Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2020

View Archived Issues

'Gut bug' has intratumoral effects

Decoy exosomes fight bacterial toxin

AbbVie begins first-in-human study of ABBV-184 in previously treated AML and NSCLC

NCI selects Curadigm's Nanoprimer technology for characterization

Mesoblast to evaluate remestemcel-L for treatment of COVID-19 lung disease

Brilacidin to be tested against COVID-19

FDA clears IND applications for phase I study of CAD-9303 in schizophrenia

Nuclear NR4A3 expression as novel diagnostic biomarker of ACC-SG

SATB2 as novel biomarker of neuroendocrine differentiation in gynecological tumors

Broadly neutralizing antibody plus latency reversing treatment evaluated in HIV trial

Novel 18F-labeled tryptophan analogue as a PET imaging probe for Shh medulloblastoma

GEMoaB initiates first-in-human study of UniCAR-T-CD123 in acute leukemias

Chinese researchers patent JAK inhibitors

Rudong Ringene Pharmaceuticals divulges FGFR inhibitors

AZD-2373 begins first-in-human trial in healthy male subjects of African ancestry

KeyBioscience discloses new compounds for diabetes

Beijing Yuezhikangtai Biomedicines presents new tyrosine kinase inhibitors

Beijing Scitech-Mq Pharmaceuticals identifies VEGFR-2 and CSF-1R inhibitors

Researchers debut open-source platform for in silico small molecule screening

Neoantigen-rich murine melanoma cell model devised to study checkpoint inhibitor responses

First phase I study of cannabinol cream INM-755 completes enrollment

Gilead presents 96-week data from DISCOVER trial of Descovy for PrEP

Tiziana accelerates development of TZLS-501 for COVID-19

Novo Nordisk initiates phase I study of NNC0472-0147 for type 2 diabetes

Nucana reports preliminary data from phase II study of Acelarin in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...